HLA-DO acts as a substrate mimic to inhibit HLA-DM by a competitive mechanism

Nature Structural and Molecular Biology

Volumn 20, Issue 1, 2013, Pages 90-98

  Guce, Abigail I ^a   Mortimer, Sarah E ^a   Yoon, Taejin ^b,c   Painter, Corrie A ^a   Jiang, Wei ^b   Mellins, Elizabeth D ^b   Stern, Lawrence J ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b STANFORD UNIVERSITY   (United States)

^c Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DM ANTIGEN; HLA DO ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ALPHA HELIX; ANTIGEN BINDING; ANTIGEN FUNCTION; ANTIGEN STRUCTURE; ARTICLE; BETA SHEET; CRYSTAL STRUCTURE; ENZYME KINETICS; HUMAN; HYDROPHOBICITY; IN VIVO STUDY; MOLECULAR MIMICRY; MUTAGENESIS; PRIORITY JOURNAL; STEADY STATE; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; BINDING SITES; CELL LINE; CRYSTALLOGRAPHY, X-RAY; DROSOPHILA MELANOGASTER; HLA-D ANTIGENS; HUMANS; MOLECULAR CHAPERONES; MUTATION; PROTEIN CONFORMATION;

MAMMALIA;

EID: 84872040972     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb.2460     Document Type: Article

References (67)

1. Denzin, L. K. & Cresswell, P. HLA-DM induces CLIP dissociation from MHC class II αβ dimers and facilitates peptide loading. Cell 82, 155-165 (1995).
2. Sloan, V. S. et al. Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 375, 802-806 (1995).
3. Ghosh, P., Amaya, M., Mellins, E. & Wiley, D. C. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 378, 457-462 (1995).
4. Morris, P. et al. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature 368, 551-554 (1994).
5. Riberdy, J. M., Newcomb, J. R., Surman, M. J., Barbosa, J. A. & Cresswell, P. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature 360, 474-477 (1992).
6. Anders, A. K. et al. HLA-DM captures partially empty HLA-DR molecules for catalyzed removal of peptide. Nat. Immunol. 12, 54-61 (2011).
7. Ferrante, A. & Gorski, J. Cutting edge: HLA-DM-mediated peptide exchange functions normally on MHC class II-peptide complexes that have been weakened by elimination of a conserved hydrogen bond. J. Immunol. 184, 1153-1158 (2010).
8. Narayan, K. et al. HLA-DM targets the hydrogen bond between the histidine at position β81 and peptide to dissociate HLA-DR-peptide complexes. Nat. Immunol. 8, 92-100 (2007).
9. Painter, C. et al. Conformational lability in the class II MHC 3-10 helix and adjacent extended strand dictate HLA-DM susceptibility and peptide exchange. Proc. Natl. Acad. Sci. USA 108, 19329-19334 (2011).
10. Zhou, Z., Callaway, K. A., Weber, D. A. & Jensen, P. E. Cutting edge: HLA-DM functions through a mechanism that does not require specific conserved hydrogen bonds in class II MHC-peptide complexes. J. Immunol. 183, 4187-4191 (2009).
11. Denzin, L. K., Hammond, C. & Cresswell, P. HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules. J. Exp. Med. 184, 2153-2165 (1996).
12. Kropshofer, H., Arndt, S. O., Moldenhauer, G., Hammerling, G. J. & Vogt, A. B. HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. Immunity 6, 293-302 (1997).
13. Weber, D. A., Evavold, B. D. & Jensen, P. E. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science 274, 618-620 (1996).
14. Tonnelle, C., DeMars, R. & Long, E. O. DOβ: a new β chain gene in HLA-D with a distinct regulation of expression. EMBO J. 4, 2839-2847 (1985).
15. Douek, D. C. & Altmann, D. M. T-cell apoptosis and differential human leucocyte antigen class II expression in human thymus. Immunology 99, 249-256 (2000).
16. Hornell, T. M. et al. Human dendritic cell expression of HLA-DO is subset specific and regulated by maturation. J. Immunol. 176, 3536-3547 (2006).
17. Karlsson, L., Surh, C. D., Sprent, J. & Peterson, P. A. A novel class II MHC molecule with unusual tissue distribution. Nature 351, 485-488 (1991).
18. Chen, X. et al. Regulated expression of human histocompatibility leukocyte antigen (HLA)-DO during antigen-dependent and antigen-independent phases of B cell development. J. Exp. Med. 195, 1053-1062 (2002).
19. Glazier, K. S. et al. Germinal center B cells regulate their capability to present antigen by modulation of HLA-DO. J. Exp. Med. 195, 1063-1069 (2002).
20. Chen, X., Reed-Loisel, L. M., Karlsson, L. & Jensen, P. E. H2-O expression in primary dendritic cells. J. Immunol. 176, 3548-3556 (2006).
21. Denzin, L. K., Fallas, J. L., Prendes, M. & Yi, W. Right place, right time, right peptide: DO keeps DM focused. Immunol. Rev. 207, 279-292 (2005).
22. Jensen, P. E. Antigen processing: HLA-DO-a hitchhiking inhibitor of HLA-DM. Curr. Biol. 8, R128-R131 (1998).
23. Yi, W. et al. Targeted regulation of self-peptide presentation prevents type I diabetes in mice without disrupting general immunocompetence. J. Clin. Invest. 120, 1324-1336 (2010).
24. Perraudeau, M. et al. Altered major histocompatibility complex class II peptide loading in H2-O-deficient mice. Eur. J. Immunol. 30, 2871-2880 (2000).
25. van Ham, S. M. et al. HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading. Curr. Biol. 7, 950-957 (1997).
26. Alfonso, C. et al. Analysis of H2-O influence on antigen presentation by B cells. J. Immunol. 171, 2331-2337 (2003).
27. Alfonso, C., Williams, G. S. & Karlsson, L. H2-O influence on antigen presentation in H2-E-expressing mice. Eur. J. Immunol. 33, 2014-2021 (2003).
28. Liljedahl, M. et al. Altered antigen presentation in mice lacking H2-O. Immunity 8, 233-243 (1998).
29. Denzin, L. K., Sant'Angelo, D. B., Hammond, C., Surman, M. J. & Cresswell, P. Negative regulation by HLA-DO of MHC class II-restricted antigen processing. Science 278, 106-109 (1997).
30. Liljedahl, M. et al. HLA-DO is a lysosomal resident which requires association with HLA-DM for efficient intracellular transport. EMBO J. 15, 4817-4824 (1996).
31. Yoon, T. et al. Mapping the DO/DM complex by FRET and mutagenesis. Proc. Natl. Acad. Sci. USA 109, 11276-11281 (2012).
32. Fallas, J. L. et al. Ectopic expression of HLA-DO in mouse dendritic cells diminishes MHC class II antigen presentation. J. Immunol. 173, 1549-1560 (2004).
33. Thibodeau, J. et al. Conserved structural features between HLA-DOβ and-DRβ. Mol. Immunol. 35, 885-893 (1998).
34. Kropshofer, H. et al. A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules. EMBO J. 17, 2971-2981 (1998).
35. Deshaies, F. et al. A point mutation in the groove of HLA-DO allows egress from the endoplasmic reticulum independent of HLA-DM. Proc. Natl. Acad. Sci. USA 102, 6443-6448 (2005).
36. Fremont, D. H., Crawford, F., Marrack, P., Hendrickson, W. A. & Kappler, J. Crystal structure of mouse H2-M. Immunity 9, 385-393 (1998).
37. Mosyak, L., Zaller, D. M. & Wiley, D. C. The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation. Immunity 9, 377-383 (1998).
38. Nicholson, M. J. et al. Small molecules that enhance the catalytic efficiency of HLA-DM. J. Immunol. 176, 4208-4220 (2006).
39. Pashine, A. et al. Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides. Immunity 19, 183-192 (2003).
40. Doebele, R. C., Busch, R., Scott, H. M., Pashine, A. & Mellins, E. D. Determination of the HLA-DM interaction site on HLA-DR molecules. Immunity 13, 517-527 (2000).
41. Vogt, A. B., Kropshofer, H., Moldenhauer, G. & Hammerling, G. J. Kinetic analysis of peptide loading onto HLA-DR molecules mediated by HLA-DM. Proc. Natl. Acad. Sci. USA 93, 9724-9729 (1996).
42. Copeland, R. Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis 2nd edn., Ch. 9 (Wiley-VCH, 2000).
43. Williams, J. W. & Morrison, J. F. The kinetics of reversible tight-binding inhibition. Methods Enzymol. 63, 437-467 (1979).
44. Zwart, W. et al. Spatial separation of HLA-DM/HLA-DR interactions within MIIC and phagosome-induced immune escape. Immunity 22, 221-233 (2005).
45. van Ham, M. et al. Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO. J. Exp. Med. 191, 1127-1136 (2000).
46. van Lith, M. et al. Regulation of MHC class II antigen presentation by sorting of recycling HLA-DM/DO and class II within the multivesicular body. J. Immunol. 167, 884-892 (2001).
47. Xiu, F. et al. Cutting edge: HLA-DO impairs the incorporation of HLA-DM into exosomes. J. Immunol. 187, 1547-1551 (2011).
48. Gondré-Lewis, T. A., Moquin, A. E. & Drake, J. R. Prolonged antigen persistence within nonterminal late endocytic compartments of antigen-specific B lymphocytes. J. Immunol. 166, 6657-6664 (2001).
49. Sant, A. J., Braunstein, N. S. & Germain, R. N. Predominant role of amino-terminal sequences in dictating efficiency of class II major histocompatibility complex αβ dimer expression. Proc. Natl. Acad. Sci. USA 84, 8065-8069 (1987).
50. Sant, A. J., Hendrix, L. R., Coligan, J. E., Maloy, W. L. & Germain, R. N. Defective intracellular transport as a common mechanism limiting expression of inappropriately paired class II major histocompatibility complex α/β chains. J. Exp. Med. 174, 799-808 (1991).
51. Rinderknecht, C. H. et al. DM influences the abundance of major histocompatibility complex class II alleles with low affinity for class II-associated invariant chain peptides via multiple mechanisms. Immunology 131, 18-32 (2010).
52. Ferrante, A., Anderson, M. W., Klug, C. S. & Gorski, J. HLA-DM mediates epitope selection by a "compare-exchange" mechanism when a potential peptide pool is available. PLoS ONE 3, e3722 (2008).
53. Painter, C. A., Cruz, A., Lopez, G. E., Stern, L. J. & Zavala-Ruiz, Z. Model for the peptide-free conformation of class II MHC proteins. PLoS ONE 3, e2403 (2008).
54. Weiss, M. S. Global indicators of X-ray data quality. J. Appl. Crystallogr. 34, 130-135 (2001).
55. Busch, R., Doebele, R. C., von Scheven, E., Fahrni, J. & Mellins, E. D. Aberrant intermolecular disulfide bonding in a mutant HLA-DM molecule: implications for assembly, maturation, and function. J. Immunol. 160, 734-743 (1998).
56. Marsh, S. G. E. et al. Nomenclature for factors of the HLA system. Tissue Antigens 75, 291-455 (2010).
57. Frayser, M., Sato, A. K., Xu, L. & Stern, L. J. Empty and peptide-loaded class II major histocompatibility complex proteins produced by expression in Escherichia coli and folding in vitro. Protein Expr. Purif. 15, 105-114 (1999).
58. Joshi, R. V., Zarutskie, J. A. & Stern, L. J. A three-step kinetic mechanism for peptide binding to MHC class II proteins. Biochemistry 39, 3751-3762 (2000).
59. Zarutskie, J. A. et al. The kinetic basis of peptide exchange catalysis by HLA-DM. Proc. Natl. Acad. Sci. USA 98, 12450-12455 (2001).
60. Otwinoski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
61. McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
62. Brünger, A. T. et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54, 905-921 (1998).
63. Terwilliger, T. C. Maximum-likelihood density modification. Acta Crystallogr. D Biol. Crystallogr. 56, 965-972 (2000).
64. Sheldrick, G. M. & Schneider, T. R. SHELXL: high-resolution refinement. Methods Enzymol. 277, 319-343 (1997).
65. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221 (2010).
66. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
67. Karplus, P. A. & Diederichs, K. Linking crystallographic model and data quality. Science 336, 1030-1033 (2012).